OpenDNA

Company Overview

Snapshot

Founded in September 2018 by Eran Feldhay and Erez Ornan, OpenDNA operates with 1–10 employees. The company has raised $6.02 million across six funding rounds from four investors. In November 2023, OpenDNA partnered with PartnerMD to integrate its AI-based genetic risk testing for cardiometabolic diseases into PartnerMD's patient services.

Business overview

OpenDNA develops an AI platform that integrates clinical and genomic data analysis to predict and prevent polygenic diseases. Its core technology leverages AI to create prediction models that identify high-risk patients and inform targeted prevention strategies. Initially applied to cardiometabolic syndrome, the company plans to expand its technology to other complex polygenic conditions such as cancer, chronic kidney failure, and autoimmune diseases. OpenDNA serves healthcare providers and payers within the Health Tech & Life Sciences sector, enabling them to implement genomic precision medicine and population genomics approaches.

Strategic signal

In November 2023, OpenDNA announced a strategic partnership with PartnerMD to provide AI-based genetic risk testing for cardiometabolic diseases. This collaboration is significant as it validates OpenDNA's technology through integration with a healthcare provider network, expanding its market reach and demonstrating the practical application of its genomic AI platform in clinical settings. For investors, this signals strong commercial traction and potential for broader adoption within the precision medicine landscape.

Company Intelligence Q&A

What was the outcome of OpenDNA's clinical study announced in June 2023?

In June 2023, OpenDNA announced the successful conclusion of a 150-patient clinical study. This milestone validates the efficacy of its AI-based genetic risk testing for cardiometabolic diseases.

What strategic partnership did OpenDNA announce in November 2023?

In November 2023, OpenDNA partnered with PartnerMD to integrate its AI-based genetic risk testing for cardiometabolic diseases into PartnerMD's patient services. This collaboration aims to provide patients with advanced genetic risk assessments.

What agreement did OpenDNA establish with Mayo Clinic in March 2022?

In March 2022, OpenDNA announced a know-how and research agreement with Mayo Clinic. This agreement was part of a pilot clinical study focused on cardiovascular disease prevention, leveraging OpenDNA's technology.

Which investor participated in OpenDNA's December 2024 funding round?

In December 2024, OpenDNA secured funding from PipelBiz through an equity crowdfunding round.

What type of funding did OpenDNA receive in June 2020?

In June 2020, OpenDNA received seed funding from investors including MindUP and Israel Innovation Authority.